Good, that probably means that they'll survive the

Good, that probably means that they'll survive the failure of their clinical trial. I hate to hear about real biotech companies encountering difficulties. (As opposed to companies like NNVC that have achieved exactly nothing after years of leading shareholders on. Those kinds of companies scare investors away from investing in other small biotechs.)